EyePoint (EYPT) Change in Accured Expenses (2010 - 2026)
EyePoint (EYPT) reported Change in Accured Expenses of $571000.0 for Q1 2026, down 88.52% on a YoY basis from $5.0 million in Q1 2025, and down 90.84% sequentially from $6.2 million in Q4 2025.
EyePoint (EYPT) Change in Accured Expenses (2010 - 2026) Analysis & Trends
EyePoint (EYPT) has 17 years of Change in Accured Expenses data on file, last reported at $571000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 88.52% year-over-year to $571000.0; the trailing twelve-month figure through Mar 2026 stood at $274000.0 (down 97.74% YoY), and the FY2025 full-year result was $4.7 million, down 18.39% from the prior year.
- Change in Accured Expenses fell to $571000.0 in Q1 2026, from $6.2 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $8.1 million in Q4 2024 to a low of -$6.0 million in Q3 2024.
- A 5-year average of $805647.1 and a median of $571000.0 in 2026 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses tumbled 263.13% in 2023 and jumped 1017.17% in 2024, its largest moves.
- Tracing EYPT's Change in Accured Expenses over 5 years: stood at -$483000.0 in 2022, then soared by 250.72% to $728000.0 in 2023, then jumped by 1017.17% to $8.1 million in 2024, then retreated by 23.39% to $6.2 million in 2025, then sank by 90.84% to $571000.0 in 2026.
- Business Quant data shows EYPT's Change in Accured Expenses at $571000.0 in Q1 2026, $6.2 million in Q4 2025, and -$3.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | 571,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 571,000.00 |
| Mar 31, 2026 | 571,000.00 |
| Dec 31, 2025 | 6.23 Mn |
| Dec 31, 2025 | 6.23 Mn |
| Sep 30, 2025 | -3.06 Mn |
| Sep 30, 2025 | -3.06 Mn |
| Jun 30, 2025 | -3.47 Mn |
| Jun 30, 2025 | -3.47 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Dec 31, 2024 | 8.13 Mn |
| Dec 31, 2024 | 8.13 Mn |
| Sep 30, 2024 | -6.04 Mn |
| Sep 30, 2024 | -6.04 Mn |
| Jun 30, 2024 | 5.07 Mn |
| Jun 30, 2024 | 5.07 Mn |
| Mar 31, 2024 | -1.43 Mn |
| Mar 31, 2024 | -1.43 Mn |
| Dec 31, 2023 | 728,000.00 |
| Dec 31, 2023 | 728,000.00 |